Omnicell's stock surged 14.84% in after-hours trading on Thursday, reversing earlier losses.
The healthcare technology company reported mixed fourth-quarter results but issued better-than-expected revenue guidance for the first quarter of 2026. While Q4 non-GAAP earnings per share fell short of analyst estimates, revenue slightly exceeded expectations. More importantly, the company projected Q1 revenue of $300 million to $310 million, well above the $281.5 million analysts had anticipated.
Additionally, analysts have recently provided insights on Omnicell, indicating optimism about the healthcare sector and the company's prospects. This combination of strong forward revenue guidance and positive analyst sentiment appears to have driven the after-hours rally.